Demographic, physiologic and radiographic characteristics of COPD patients taking chronic systemic corticosteroids

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 1, 2012, Pages 29-35

  Swift, Irene ^a   Satti, Aditi ^a   Kim, Victor ^a   Make, Barry J ^b   Newell, John ^b   Steiner, Robert M ^a   Wilson, Carla ^b   Murphy, James R ^b   Silverman, Edwin K ^c   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Emphysema; Phenotype; Prednisone

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; ASTHMA; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE EXACERBATION; DRUG USE; EMPHYSEMA; EXERCISE TOLERANCE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OXYGEN SATURATION; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; SCORING SYSTEM; SMOKING HABIT; SYSTEMIC THERAPY; WALKING;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEBULIZERS AND VAPORIZERS; OXYGEN; OXYGEN INHALATION THERAPY; PREDNISONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; SMOKING; SPIROMETRY; THEOPHYLLINE; UNITED STATES; WALKING;

EID: 84856609281     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.634454     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung, and Blood Institute, April 2001 (revised 2009). (Available at http://www.goldcopd.org).
2. Regan E, Hokanson J, Murphy J, Make B, Lynch D, Beaty T, et al. Genetic epidemiology of COPD (COPDGene®) study design. COPD 2010; 7:32-43.
3. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-187. (Pubitemid 29036522)
4. Pellefrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Series "ATS-ERS Task Force: Standardisation of lung function testing". Eur Respir J 2005; 26:948-968.
5. Celli BR, Cote CG, Marin JM, Casanova C, de Oca MM, Mendez RA, et al. Th e body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. NEJM 2004; 350:1005-1012. (Pubitemid 38269277)
6. ATS Committee on Profi ciency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.
7. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8:1398-1420.
8. Anthonisen NR, Wright EC, Hodgkin JE, and the IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Resp Dis 1986; 133:14-20. (Pubitemid 16189089)
9. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease: a 15-year follow-up study. Am Rev Respir Dis 1979; 119:895-902. (Pubitemid 9208242)
10. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 1221:1434-1440. (Pubitemid 34499652)
11. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994; 7:725-729. (Pubitemid 24122970)
12. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, et al. Predictors of mortality in patients with emphysema and severe airfl ow obstruction. Am J Respir Crit Care Med. 2006; 173:1326-1334. (Pubitemid 43900706)
13. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. Th e 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23:28-33. (Pubitemid 38088492)
14. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:544-49.
15. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131:696-704. (Pubitemid 46446859)
16. Seemungal TAR, Donaldson GC, Bhowmik A, Bhowmik A, Jeff ries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1618.
17. Sachs APE, Koeter GH, Groenier KH, van der Waaij D, Schiphuis J, Jong BM. Changes in symptoms, peak expiratory flow and sputum glora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Th orax 50:758-763.
18. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Th orax 2002; 57:847-852. (Pubitemid 35178607)
19. Connors AF Jr, Dawson NV, Th omas C, Harrell FE Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154:959-967.
20. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. Chronic obstructive pulmonary disease stage and health-related quality of life: the quality of life of chronic obstructive pulmonary disease study group. Ann Int Med 1997; 127:1072-1079. (Pubitemid 28012076)
21. Seemungal TAR, Donaldson GC, Paul EA. Eff ect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422.
22. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Th orax 2004; 59:574-580. (Pubitemid 38901515)
23. Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, et al. Airway and systemic infl ammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004. (Pubitemid 41507533)
24. Seemuungal TA, Wilkinson TAM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147.
25. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Weltzen G, Schouten O, Stam H, et al. Eff ect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102:192-196.
26. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MDL, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2000; 356:1480-1485.
27. Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005; 3. Art No: CD005374.
28. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155:542-548. (Pubitemid 27085799)